Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia

Ann Hematol. 2019 Sep;98(9):2233-2235. doi: 10.1007/s00277-019-03734-7. Epub 2019 Jun 26.

Authors

Neeraj Y Saini¹, Romil D Patel², Ankur Varma², Qaiser Bashir², Ruby Delgado², Gabriela Rondon², Akash Mukherjee², Uday Popat², Chitra Hosing², Yago Nieto², Partow Kebriaei², Donna M Weber³, Sheeba K Thomas³, Hans C Lee³, Elisabet E Manasanch³, Robert Z Orlowski³, Richard E Champlin², Muzaffar H Qazilbash², Krina K Patel³

Affiliations

¹ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. nsaini@mdanderson.org.
² Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
³ Department of Lymphoma and Myeloma, MD Anderson Cancer, Houston, TX, 77030, USA.

PMID: 31243571
DOI: 10.1007/s00277-019-03734-7

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Carmustine / administration & dosage
Cytarabine / administration & dosage
Disease-Free Survival
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation*
Humans
Male
Melphalan / administration & dosage
Middle Aged
Podophyllotoxin / administration & dosage
Survival Rate
Transplantation, Autologous
Waldenstrom Macroglobulinemia / mortality*
Waldenstrom Macroglobulinemia / therapy*

Substances

Cytarabine
Podophyllotoxin
Melphalan
Carmustine

Supplementary concepts

BEAM protocol